Inactive Instrument

News PHARMING GROUP Euronext Amsterdam

Stocks

NL0000377018

Pharmaceuticals

End-of-day quote Euronext Amsterdam
- ^EUR	-

09-14	Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja	MT
09-11	Pharming Receives Fda Approval for Joenja as First Treatment for Children with Apds in the U S	CI

All News

Mentions Relevance

09-25	Pharming Says FDA Accepts sNDA for Lower-Dose Joenja in Children With APDS	MT
09-25	Pharming Group N.V. Announces U.S. FDA Acceptance And Priority Review Of sNDA For Lower Doses Of Joenja To Treat Children With APDS	CI
09-25	Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS	GL
09-22	Pharming Group N.V. Announces Positive Phase II Topline Data For Leniolisib In PIDs With Immune Dysregulation Accepted As Late-Breaking Abstract At ESID 2026	CI
09-22	Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026	GL
09-14	FDA approves Pharming's Joenja(R) as first treatment for children with APDS in the U.S.	AQ
09-14	Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja	MT
09-11	Pharming Receives Fda Approval for Joenja as First Treatment for Children with Apds in the U S	CI
09-11	FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.	GL
09-11	Pharming Gets FDA Approval for Joenja to Treat APDS in Children Aged 4-11	MT
09-09	Pharming Group to participate in September investor conferences	GL
09-03	Pharming N : Millennium International Management LP - Pharming Group N.V. - Leiden	PU
08-13	Pharming Launches Joenja in Japan for Adult, Pediatric APDS Patients	MT
08-13	Pharming Group Launches Rare Primary Immunodeficiency Therapy Joenja in Japan	MT
08-13	Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older	GL
08-13	Pharming Group Announces Commercial Launch of Joenja in Japan for Adult and Pediatric Patients with Apds Aged 4 and Older	CI
08-04	Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference	GL
07-30	Pharming Group N.V., Q2 2026 Earnings Call, Jul 30, 2026
07-30	Pharming Group's Q2 Earnings, Revenue Fall; 2026 Revenue Outlook Updated	MT
07-30	Pharming Group N.V. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-30	Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use	GL
07-30	Pharming Group N.V. Revises Earnings Guidance for the Year 2026	CI
07-16	Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30	GL
07-09	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden	PU
07-04	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden	PU